159 related articles for article (PubMed ID: 29087665)
1. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer.
Shank BR; Nguyen PAA; Pherson EC
Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665
[No Abstract] [Full Text] [Related]
2. Rising Cost of Anticancer Medications in the United States.
Jackson K; Nahata MC
Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
[TBL] [Abstract][Full Text] [Related]
3. Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
Lotvin AM; Shrank WH; Singh SC; Falit BP; Brennan TA
Health Aff (Millwood); 2014 Oct; 33(10):1736-44. PubMed ID: 25288417
[TBL] [Abstract][Full Text] [Related]
4. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceuticals and Medical Devices: Cost Savings.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
[No Abstract] [Full Text] [Related]
6. High-Cost Users of Prescription Drugs: A Population-Based Analysis from British Columbia, Canada.
Weymann D; Smolina K; Gladstone EJ; Morgan SG
Health Serv Res; 2017 Apr; 52(2):697-719. PubMed ID: 27087391
[TBL] [Abstract][Full Text] [Related]
7. Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States.
Alghanem N; Abokwidir M; Fleischer AB; Feldman SR; Alghanem W
J Dermatolog Treat; 2017 Mar; 28(2):119-128. PubMed ID: 27241622
[TBL] [Abstract][Full Text] [Related]
8. The ongoing threat of rising drug prices: ASHP's work goes on.
Abramowitz PW
Am J Health Syst Pharm; 2017 Apr; 74(8):551-552. PubMed ID: 28336677
[No Abstract] [Full Text] [Related]
9. Implementation of a $4 generic drug program in a 340B pharmacy.
Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
[TBL] [Abstract][Full Text] [Related]
10. The true cost and benefit of medication reduction.
Aurigemma R
Del Med J; 2009 Apr; 81(4):163-4. PubMed ID: 19552220
[No Abstract] [Full Text] [Related]
11. Overspending driven by oversized single dose vials of cancer drugs.
Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
[No Abstract] [Full Text] [Related]
12. Pharmacies take uniform price demands to court.
Moskowitz DB
J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
[No Abstract] [Full Text] [Related]
13. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
14. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D.
Dusetzina SB
N Engl J Med; 2022 Jun; 386(23):2164-2167. PubMed ID: 35507526
[No Abstract] [Full Text] [Related]
15. Pharmacy accessibility and cost-related underuse of prescription medications in low-income Black and Hispanic urban communities.
Qato DM; Wilder J; Zenk S; Davis A; Makelarski J; Lindau ST
J Am Pharm Assoc (2003); 2017; 57(2):162-169.e1. PubMed ID: 28153704
[TBL] [Abstract][Full Text] [Related]
16. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
Dusetzina SB; Bach PB
JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
[No Abstract] [Full Text] [Related]
17. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
18. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
Cohen J; Malins A; Shahpurwala Z
Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
[TBL] [Abstract][Full Text] [Related]
19. Pharmacy initiatives target prescription drug costs.
Stafford E
J Mich Dent Assoc; 2008 Sep; 90(9):22. PubMed ID: 19051519
[No Abstract] [Full Text] [Related]
20. THE MOST FAVORED NATIONS MODEL INTERIM FINAL RULE IS FATALLY FLAWED AND MUST BE RESCINDED-YET THE PROBLEM IT ADDRESSES DEMANDS A SOLUTION.
Rubinstein E
J Manag Care Spec Pharm; 2021 Feb; 27(2):286. PubMed ID: 33506733
[No Abstract] [Full Text] [Related]
[Next] [New Search]
